DexCom (DXCM) Earnings Date & Reports
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients... Show more
DXCM is expected to report earnings to rise 8.46% to 60 cents per share on July 23
DexCom (DXCM) Q1 2026 Earnings Recap: Revenue Beats with 15% Growth
Key Takeaways
- DexCom reported first-quarter revenue of $1.192 billion, a 15% increase year-over-year on a reported basis (12% organic), surpassing consensus estimates of approximately $1.175 billion.
- GAAP diluted earnings per share (EPS) came in at $0.51, beating expectations of $0.46 and up 89% from the prior year.
- Gross margin expanded significantly to 62.9% (GAAP), while operating margin reached 21.4%, reflecting operational efficiencies.
- Non-GAAP operating margin improved to 22.2%, with adjusted EBITDA of $364.5 million.
- Company reaffirmed full-year 2026 revenue guidance at $5.16-$5.25 billion, implying 11-13% growth.
- Shares rose approximately 3.4% in after-hours trading, signaling positive investor response to the beats.
Earnings Context and Why It Matters
As a leader in continuous glucose monitoring (CGM) systems for diabetes management, DexCom's quarterly results are closely watched by investors tracking innovation in the medical device sector. The company has benefited from strong adoption of its Dexcom G7 CGM, including a new 15-day sensor launched in the U.S. Recent expansions into type 2 diabetes patients not on insulin, via the over-the-counter Stelo platform, add growth potential amid rising diabetes prevalence. Prior quarters showed steady revenue gains but margin pressures; this report's focus on profitability amid competitive dynamics from rivals like Abbott underscores DexCom's execution, influencing stock valuation and sector sentiment.
Reported Results
DexCom delivered robust first-quarter 2026 results for the period ended March 31, 2026. Revenue reached $1.192 billion, up 15% year-over-year on a reported basis and 12% organically (excluding foreign exchange), topping consensus estimates of about $1.175 billion. U.S. revenue grew 11%, while international sales surged 26% reported (17% organic).
GAAP gross profit was $750.3 million, or 62.9% of revenue, up from 56.9% last year. GAAP operating income hit $255.3 million (21.4% margin), more than doubling year-over-year. GAAP net income stood at $199.5 million, or $0.51 diluted EPS, exceeding the $0.46 estimate and up 89% YoY. Non-GAAP diluted EPS was $0.56.
Guidance for full-year 2026 was reaffirmed, with revenue projected at $5.16-$5.25 billion, non-GAAP gross margin of 63-64%, and non-GAAP operating margin of 23-23.5%.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Following the April 30 release, DexCom shares advanced roughly 3.4% in after-hours trading to around $58, reflecting approval of the earnings beat and margin progress. Investor sentiment appeared positive on strong CGM demand and profitability gains, though some caution lingered over reaffirmed guidance not being raised, amid broader market volatility in healthcare stocks. Analysts noted healthy U.S. and international growth as supportive factors.
Forward Outlook and Key Factors to Monitor
DexCom's reaffirmed 2026 guidance signals confidence in sustained momentum, with revenue growth of 11-13% driven by Dexcom G7 expansion, including the 15-day wear sensor now available across all U.S. channels. Investors should watch adoption rates, particularly among type 2 diabetes patients not using insulin, bolstered by clinical data presented at the ATTD (Advanced Technologies & Treatments for Diabetes) conference showing A1C (average blood sugar measure) improvements.
Upcoming catalysts include the Investor Day event, where management will outline long-term strategy, and further Stelo platform enhancements like Smart Meal Logging. Margin trends remain key, with targeted non-GAAP gross margins of 63-64% amid supply chain efficiencies and scale. International expansion and reimbursement progress could accelerate organic growth.
Potential headwinds include competition in CGM, regulatory hurdles for new features, and macroeconomic pressures on healthcare spending. Track quarterly customer additions, sensor utilization rates, and guidance updates for insights into demand sustainability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices